Elevai Labs, Inc. (NASDAQ:ELAB) Short Interest Update

Elevai Labs, Inc. (NASDAQ:ELAB) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 48,800 shares, a drop of 98.1% from the November 15th total of 2,620,000 shares. Based on an average trading volume of 816,600 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Elevai Labs

An institutional investor recently bought a new position in Elevai Labs stock. Whittier Trust Co. of Nevada Inc. bought a new stake in Elevai Labs, Inc. (NASDAQ:ELAB) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 80,666 shares of the company’s stock, valued at approximately $47,000. Whittier Trust Co. of Nevada Inc. owned approximately 0.43% of Elevai Labs as of its most recent filing with the Securities and Exchange Commission. 22.22% of the stock is owned by institutional investors and hedge funds.

Elevai Labs Price Performance

Shares of NASDAQ:ELAB traded down $0.15 during midday trading on Wednesday, reaching $2.42. The company’s stock had a trading volume of 554,257 shares, compared to its average volume of 229,731. Elevai Labs has a fifty-two week low of $1.74 and a fifty-two week high of $778.00. The company has a market capitalization of $6.26 million and a P/E ratio of -0.04. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.86 and a quick ratio of 3.40. The business’s fifty day simple moving average is $10.39 and its 200-day simple moving average is $59.19.

Elevai Labs Company Profile

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.